Agios Pharmaceuticals AGIO Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's change in accrued liabilities?
- Agios Pharmaceuticals (AGIO) reported change in accrued liabilities of -$19.17M in Q1 2026.
- How has Agios Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Agios Pharmaceuticals's change in accrued liabilities increased by 26.6% year-over-year, from -$26.1M to -$19.17M.
- What is the long-term trend for Agios Pharmaceuticals's change in accrued liabilities?
- Over 2 years (2021 to 2024), Agios Pharmaceuticals's change in accrued liabilities has grown at a 648.1% compound annual growth rate (CAGR), from $66K to $3.69M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.